TETRA-ARYL CYCLOBUTANE INHIBITORS OF ANDROGEN RECEPTOR ACTION FOR THE TREATMENT OF HORMONE REFRACTORY CANCER
申请人:THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
公开号:US20160229811A1
公开(公告)日:2016-08-11
The present disclosure provides tetra-substituted cyclobutane inhibitors of Androgen Receptor Action, and methods of using such inhibitors, for the treatment of hormone-refractory cancers.
[EN] TETRA-ARYL CYCLOBUTANE INHIBITORS OF ANDROGEN RECEPTOR ACTION FOR THE TREATMENT OF HORMONE REFRACTORY CANCER<br/>[FR] INHIBITEURS TÉTRA-ARYLE-CYCLOBUTANE DE L'ACTION DU RÉCEPTEUR DES ANDROGÈNES POUR LE TRAITEMENT D'UN CANCER RÉFRACTAIRE AUX HORMONES
申请人:UNIV ILLINOIS
公开号:WO2015048246A1
公开(公告)日:2015-04-02
The present disclosure provides tetra-substituted cyclobutane inhibitors of Androgen Receptor Action, and methods of using such inhibitors, for the treatment of hormone-refractory cancers.
Magnesium-promoted reductivesilylation of 2- and 4-vinylpyridines with chlorotrialkylsilanes in N-methylpyrrolidinone at room temperature led to the selective formation of a variety of the corresponding β-mono-silylated compounds at the terminal carbon atom in good to excellent yields, whereas silylation of 3-vinylpyridine under the same reduction conditions failed to give a complex mixture of silylated